<DOC>
	<DOCNO>NCT02251431</DOCNO>
	<brief_summary>Among adult individual type 2 diabetes mellitus risk heart failure impaired relaxation heart mildly reduce kidney filtration function ( Type 4 cardiorenal syndrome ) trial evaluate quantitative impact 38 week treatment exenatide extended-release injection versus placebo . cardiac biomarker blood test score , cardiac fibrosis see magnetic resonance scanning , cardiac strain identify ultrasonography strain rate imaging , kidney urine biomarker score .</brief_summary>
	<brief_title>Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome</brief_title>
	<detailed_description>Primary Aim Among adult individual type 2 diabetes mellitus ( T2DM ) risk diastolic heart failure ( DHF ) mildly reduce renal filtration function ( Type 4 cardiorenal syndrome ) , evaluate quantitative impact MISS ( myocardial injury summary score ) cardiac biomarker score , cardiac fibrosis MRI , cardiac strain ultrasonography strain rate imaging , KISS ( kidney injury summary score ) kidney biomarker score 38 week treatment exenatide extended-release placebo . Secondary Aim To evaluate inter-relationships demographic , clinical , biochemical variable ( MISS score , KISS score ) progressive cardiac fibrosis assess MRI , strain-rate imaging , adult individual T2DM risk DHF ( Type 4 cardiorenal syndrome ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Age ≥ 18 Type 2 diabetes mellitus hemoglobin A1C 6.69.9 % without use insulin Estimated glomerular filtration rate ( eGFR ) 50 90 ml/min/1.73 m2 Allergy intolerance gadolinium Implanted cardiac pacemaker , defibrillator , loop recorder , implant metallic device Any metallic implant device contraindication MRI scan eGFR &lt; 50 ml/min/1.73 m2 eGFR &gt; 90 ml/min/1.73 m2 Patient ever treat approved investigational GLP1 receptor agonist e.g . BYETTA™ ( exenatide ) , BYDUREON™ ( Exenatide extendedrelease ) , VICTOZA™ ( liraglutide ) , taspoglutide Patient enrol another experimental protocol involve use investigational drug device , intervention would interfere conduct trial . Disorders iron metabolism Collagen vascular disease Myocardial infarction Use DDP4 inhibitor , PPAR gamma agonist Pregnancy plan pregnancy trial period Hemoglobin A1C ≥ 10.0 % &lt; 6.6 % Fasting glucose ≥ 260 mg/dl Clinically significant abnormal baseline laboratory Morbid obesity body girth prohibit ability undergo echocardiography MRI scan highquality image result Renal transplantation Severe gastrointestinal , liver , neurodegenerative disease Decompensated liver cirrhosis ( ChildPugh score &gt; 7 ) New York Heart Association Class III IV heart failure Patients alanine aminotransaminase ( ALT ) great 5 time upper limit reference range . Prior pancreatitis Personal family history medullary thyroid adenoma carcinoma ( MTC ) Multiple Endocrine Neoplasia syndrome type 2 ( MEN 2 ) . History severe hypoglycemia Prior bariatric surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>diastolic function</keyword>
	<keyword>cardiac fibrosis</keyword>
	<keyword>cardiac strain</keyword>
	<keyword>cardiac biomarker</keyword>
	<keyword>renal biomarker</keyword>
</DOC>